#	Pagina
attuale pagina	/open-h2020/projects/226448/index.html

Opendata, web and dolomites

FAIR SIGNED

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

FAIR project word cloud

Explore the words cloud of the FAIR project. It provides you a very rough idea of what is the project "FAIR" about.

effectiveness capacity mortality site preclinical leverages rapid acceptability outcome morbidity markers safety device pipeline validation models flagellin stakeholders report modalities strengthens optimal fair bacterial relative constitute airway innovation curative defences nebuliser trials antimicrobial epithelial patients analyze immune protection emergence pharmacodynamics straightforward course biology assessing resistance benefit treatment mechanisms faced pneumonia gain public recommendations outcomes enrichment trial clinical cohorts amr drug adjunct treatments simulation immunomodulatory antibiotics aerosol health therapy plan subpopulation pharmacokinetics resistant nebulized overcome avenues model infection industrial predict economic nebulization infections care standard relevance action antibiotic alone therapeutic host innate worldwide enhances stratification

Project "FAIR" data sheet

The following table provides information about the project.

Coordinator	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	10˙162˙903 €
EC max contribution	10˙162˙903 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2019-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-01-01 to 2024-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	3˙701˙150.00
2	STATENS SERUM INSTITUT STATENS SERUM INSTITUT Organization address address: ARTILLERIVEJ 5 city: KOBENHAVN S postcode: 2300 website: www.ssi.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (KOBENHAVN S)	participant	2˙057˙770.00
3	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Organization address address: MEIBERGDREEF 15 city: AMSTERDAM postcode: 1105AZ website: www.amc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	1˙200˙170.00
4	CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS Organization address address: BOULEVARD TONELLE 2 city: TOURS CEDEX 9 postcode: 37044 website: www.chu-tours.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (TOURS CEDEX 9)	participant	644˙940.00
5	FREIE UNIVERSITAET BERLIN FREIE UNIVERSITAET BERLIN Organization address address: KAISERSWERTHER STRASSE 16-18 city: BERLIN postcode: 14195 website: www.fu-berlin.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	567˙750.00
6	EPITHELIX SARL EPITHELIX SARL Organization address address: CHEMIN DES AULX 14 city: PLAN LES OUATES postcode: 1228 website: www.epithelix.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (PLAN LES OUATES)	participant	496˙000.00
7	UNIVERSITE DE LILLE UNIVERSITE DE LILLE Organization address address: 42 RUE PAUL DUEZ city: LILLE postcode: 59800 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LILLE)	participant	380˙687.00
8	UNIVERSITY OF SOUTHAMPTON UNIVERSITY OF SOUTHAMPTON Organization address address: Highfield city: SOUTHAMPTON postcode: SO17 1BJ website: http://www.southampton.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (SOUTHAMPTON)	participant	367˙186.00
9	INSERM - TRANSFERT SA INSERM - TRANSFERT SA Organization address address: RUE WATT 7 city: PARIS postcode: 75013 website: www.inserm-transfert.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	300˙750.00
10	EUROPEAN RESPIRATORY SOCIETY EUROPEAN RESPIRATORY SOCIETY Organization address address: AVENUE SAINTE LUCE 4 city: LAUSANNE postcode: 1003 website: www.ersnet.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (LAUSANNE)	participant	235˙812.00
11	AEROGEN LTD AEROGEN LTD Organization address address: IDA BUSINESS PARK DANGAN city: GALWAY postcode: H91 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (GALWAY)	participant	210˙687.00

Map

Project objective

Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure. The FAIR consortium aims at assessing an adjunct to antibiotic therapy as an emerging concept of overcome AMR in pneumonia. The project leverages (i) a unique immunomodulatory flagellin that enhances airway epithelial innate immune defences and increases the therapeutic outcome relative to antibiotic alone, and (ii) airway-specific aerosol delivery by nebulization.

FAIR’s objectives are to: • develop nebulization modalities for optimal airway targeting and rapid action at the infection site • demonstrate that nebulized flagellin strengthens the response to antibiotics in relevant preclinical models of antibiotic-resistant pneumonia • identify host immune factors required for the gain of protection with systems biology • implement pharmacokinetics/pharmacodynamics model-based design and simulation for clinical validation • assess nebulized flagellin’s safety in a Phase I clinical trial. • analyze the acceptability and economic relevance of the therapy • identify stratification markers that predict the course of pneumonia and treatment in antibiotic-treated cohorts.

Expected outcomes include the enrichment of the pipeline of novel treatments against pneumonia, reinforcement of EU capacity to control AMR and infections, the Phase I safety report on nebulized flagellin, recommendations for future trials, and acceptability by the stakeholders and cost-effectiveness for public health. FAIR will develop new avenues of research on mechanisms of action of the adjunct flagellin, and will define (for future trials) the subpopulation of patients that might benefit most from this treatment. Our industrial partnerships and exploitation plan will enable straightforward development of drug and nebuliser device, and bring innovation to the patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FAIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More